Penumbra, Inc. $PEN Stock Position Lowered by Algert Global LLC

Algert Global LLC decreased its position in Penumbra, Inc. (NYSE:PEN - Free Report) by 72.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,344 shares of the company's stock after selling 24,131 shares during the quarter. Algert Global LLC's holdings in Penumbra were worth $2,950,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Penumbra during the 2nd quarter valued at about $25,000. Larson Financial Group LLC raised its holdings in shares of Penumbra by 4,100.0% in the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company's stock worth $26,000 after purchasing an additional 82 shares in the last quarter. CIBC Private Wealth Group LLC lifted its stake in Penumbra by 2,700.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company's stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in Penumbra during the fourth quarter valued at approximately $27,000. Finally, Keating Financial Advisory Services Inc. bought a new stake in Penumbra during the second quarter worth approximately $31,000. Institutional investors own 88.88% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Penumbra in a research report on Friday, July 17th. Royal Bank Of Canada reiterated a "sector perform" rating and set a $374.00 price objective on shares of Penumbra in a research report on Thursday, June 11th. Citigroup reduced their price objective on Penumbra from $374.00 to $350.00 and set a "neutral" rating for the company in a research note on Thursday, May 7th. Evercore restated an "outperform" rating and issued a $320.00 target price on shares of Penumbra in a report on Monday, July 6th. Finally, Wall Street Zen raised Penumbra to a "hold" rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $367.07.

Penumbra Trading Up 0.2%

Penumbra stock opened at $321.58 on Friday. The company's fifty day simple moving average is $320.71 and its 200-day simple moving average is $326.86. The company has a quick ratio of 3.86, a current ratio of 5.75 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41. The stock has a market cap of $12.67 billion, a P/E ratio of 79.01, a P/E/G ratio of 1.99 and a beta of 0.70.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.16 by ($0.28). The firm had revenue of $390.05 million for the quarter, compared to analyst estimates of $389.64 million. Penumbra had a net margin of 10.67% and a return on equity of 10.50%. Penumbra's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 EPS. As a group, sell-side analysts forecast that Penumbra, Inc. will post 5.02 EPS for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source